Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Overactive bladder is a common problem among adult women. Darifenacin is an antimuscarinic drug that is frequently used as part of the management of the condition. However, current evidence backing its use is limited. This study aims to address Darifenacin's effectiveness in adjunct to physiotherapy in treating symptoms due to overactive bladder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad de Valparaiso
• Collaborator: Recalcine (GynoPharm)
• Treatments: Darifenacin

Criteria

Inclusion Criteria:

• Patients with overactive bladder as diagnosed and confirmed by a urologist.

• Able to answer the ICIC, King's Health Questionnaire and Overactive Bladder Questionnaire.

• Able and willing to receive urodynamic studies.

Exclusion Criteria:

• History of pelvic radiotherapy.

• Recent pelvic surgery (<1 year).

• History of anti-incontinence surgery.

• Pregnancy.